AnatomyDiseasesChemicals and DrugsAnalytical, Diagnostic and Therapeutic Techniques and EquipmentPhenomena and ProcessesDisciplines and OccupationsAnthropology, Education, Sociology and Social PhenomenaHumanitiesInformation ScienceHealth CareGeographicals
ChemoradiotherapyRadiotherapyRadiotherapy, AdjuvantChemoradiotherapy, AdjuvantRadiotherapy DosageCombined Modality TherapyChemotherapy, AdjuvantRadiotherapy, ConformalFluorouracilAdjuvants, ImmunologicAntineoplastic Combined Chemotherapy ProtocolsCisplatinTreatment OutcomeNeoadjuvant TherapyEsophageal NeoplasmsRectal NeoplasmsDose FractionationCarcinoma, Squamous CellNeoplasm StagingRadiotherapy, Intensity-ModulatedHead and Neck NeoplasmsRadiotherapy, High-EnergyDisease-Free SurvivalRadiation InjuriesRadiotherapy Planning, Computer-AssistedNeoplasm Recurrence, LocalSurvival AnalysisSurvival RateNasopharyngeal NeoplasmsEsophagectomyRetrospective StudiesAdenocarcinomaPrognosisFreund's AdjuvantLung NeoplasmsBrachytherapyAntineoplastic AgentsFollow-Up StudiesRadiotherapy, Computer-AssistedKaplan-Meier EstimateOrgan Sparing TreatmentsRadiotherapy, Image-GuidedDeoxycytidineLaryngeal NeoplasmsAntimetabolites, AntineoplasticInduction ChemotherapyHypopharyngeal NeoplasmsRadiation-Sensitizing AgentsRadiation OncologyDose-Response Relationship, RadiationDrug Administration ScheduleCarcinoma, Non-Small-Cell LungCarboplatinOropharyngeal NeoplasmsPreoperative CarePositron-Emission TomographyBrain NeoplasmsPelvic NeoplasmsMucositisLymphatic MetastasisRadiation PneumonitisDeglutition DisordersUterine Cervical NeoplasmsTime FactorsRadiation ToleranceRemission InductionBreast NeoplasmsRadiation DosagePaclitaxelTaxoidsAdjuvants, PharmaceuticRadiosurgeryTomography, X-Ray ComputedDigestive System Surgical ProceduresLeucovorinLaryngectomyFeasibility StudiesFluorodeoxyglucose F18CarcinomaAnus NeoplasmsLymphatic IrradiationPancreatic NeoplasmsOrganoplatinum CompoundsVincristineCranial IrradiationDacarbazineLymph Node ExcisionPostoperative CareSalvage TherapyEsophagitisCyclophosphamideHydroxyureaRadiopharmaceuticalsProspective StudiesTegafurAntineoplastic Agents, AlkylatingNeoplasms, Second PrimaryStomatitisEsophagogastric JunctionOtorhinolaryngologic Neoplasms
Chemotherapy or radiotherapyConcurrentChemoPostoperativeAddition of adjuvant chemotherapyPelvicIncluding radiotherapy aloneEither chemoradiotherapyEndometrial cancerResectionPreoperativeNeoadjuvant chemoradiotherapyToxicityRecurrenceTumorPancreaticCombines chemotherapyImproves survivalSystemic treatmentsOncologyRectalPatients treatedRadiationTreatmentFluorouracilSurgeryRandomly assigned to receiveSquamousTherapyRelapseTrialsOxaliplatinSurvival in patientsPositive nodesCancersLung cancerMedianDetermine the optimalHigh-riskMetastasisCombinationStandard of cSignificantlyResults
Chemotherapy or radiotherapy1
Concurrent11
  • The chemoradiotherapy regimen consisted of cisplatin (50 mg/m 2 ) on days 1 and 29 concurrent with volume-directed external-beam radiation therapy, followed by carboplatin given at a dose to achieve an area under the concentration-time curve (AUC) of 5-6 plus paclitaxel (175 mg/m 2 every 21 days for four cycles). (medscape.com)
  • We aimed to evaluate the safety and efficacy of adding capecitabine (a known radiosensitizer by direct and abscopal effects) to concurrent radiation in the adjuvant setting after resection of pancreatic adenocarcinoma. (iiarjournals.org)
  • Patients and Methods: We conducted a retrospective study of 63 patients diagnosed from 2004-2013 with histopathologically-confirmed stage I/II pancreatic cancer treated with a surgical resection followed by adjuvant concurrent chemoradiation to at least 45 Gy using 3D planning and capecitabine at 1,600 mg/m 2 /day (Monday-Friday) for 6 weeks. (iiarjournals.org)
  • Of the 63 patients reviewed, 61 patients (97%) completed concurrent chemoradiotherapy. (iiarjournals.org)
  • Otherwise, adverse reactions during concurrent chemoradiotherapy were well-tolerated and the majority were Common Terminology Criteria for Adverse Events grades 1 and 2. (iiarjournals.org)
  • Conclusion: Concurrent chemoradiation using capecitabine as a radiosensitizer in the adjuvant setting for pancreatic cancer was completed by the vast majority of patients in this series. (iiarjournals.org)
  • Nasopharyngeal carcinoma (NPC) patients with N2-3 diseases are prone to develop distant metastasis even treated with standard concurrent chemoradiotherapy (CCRT). (oncotarget.com)
  • Platinum-based concurrent chemoradiotherapy represents the gold standard in the treatment of locally advanced nasopharyngeal carcinoma (NPC) [ 1 , 2 ] in the era of 2D radiotherapy. (oncotarget.com)
  • Treatments were assigned based on clinical TNM stage and patient health: stage I patients received radiotherapy alone, stage II patients received radiotherapy alone or platinum-based concurrent radiochemotherapy, and advanced-stage patients (stage III through stage IV) were given concurrent chemoradiotherapy and neoadjuvant or adjuvant chemotherapy. (cancertherapyadvisor.com)
  • Triweekly XELOX or capecitabine concurrent with neoadjuvant radiotherapy leads to similar long-term survival outcomes, acute toxicities and surgical complications in LARC patients. (biomedcentral.com)
  • Adjuvant durvalumab after concurrent chemoradiotherapy for patients with unresectable stage III NSCLC harbouring uncommon genomic alterations. (cdc.gov)
Chemo9
  • Although surgical treatment with adjuvant chemo-radiotherapy, targeted therapy and immunotherapy have been used in patients with this disease, the long-term survival is still disappointing[ 6 , 7 ]. (ijpsonline.com)
  • Treatment options for NSCLC depend upon disease stage and range from surgical resection or radiotherapy (stage 1) through to surgery and adjuvant chemotherapy or chemo-radiotherapy for those with stage 3. (hospitalhealthcare.com)
  • A total of 363 plasma samples from 88 patients with early-stage NSCLC (stages 1, 2 and 3) treated with curative intent surgery (61), surgery and adjuvant chemotherapy/radiotherapy (8) and chemo-radiotherapy (19) were included in the study. (hospitalhealthcare.com)
  • The beneficial effect of chemo radiotherapy for subgroups of patients with positive nodes seems likely, although more data are needed before a definite conclusion can be made. (dermatoljournal.com)
  • Standard treatment involves surgery followed by adjuvant chemo/radiotherapy as appropriate. (aku.edu)
  • The aim of this study was to compare survival and toxicity after completed hysterectomy followed by adjuvant (chemo-)radiotherapy versus abandoned hysterectomy and primary treatment with chemoradiotherapy (CRT). (amsterdamumc.org)
  • In the RHL group, hysterectomy was completed followed by adjuvant (chemo-)radiotherapy. (amsterdamumc.org)
  • In patients with clinically N0 early-stage cervical cancer with intraoperative detection of positive nodes, completing RHL followed by adjuvant (chemo-)radiotherapy may result in a better pelvic control compared with abandoning hysterectomy and treatment with chemoradiotherapy. (amsterdamumc.org)
  • Patients who have received prior neo-adjuvant, adjuvant chemotherapy, radiotherapy, or chemo-radiotherapy with curative intent for non-metastatic disease must have experienced a treatment free interval of at least 6 months from enrollment since the last chemotherapy, radiotherapy, or chemo-radiotherapy cycle. (genentech-clinicaltrials.com)
Postoperative4
Addition of adjuvant chemotherapy2
  • The results showed an increase in failure-free survival, 75.5% in the chemoradiotherapy arm, compared with 68.6% in the patients treated with radiation only, but the 5-year survival rate did not improve with the addition of adjuvant chemotherapy. (medpagetoday.com)
  • The addition of adjuvant chemotherapy seemed to provide benefits to patients with N3 stage NPC and the current study may indicate the need for further randomized investigation. (oncotarget.com)
Pelvic2
  • One of these is the PORTEC-3 trial, which investigated adjuvant chemoradiotherapy vs pelvic radiotherapy alone for women with high-risk endometrial cancer. (medscape.com)
  • Our trial clearly demonstrates that adjuvant pelvic radiation should remain the standard of care for high-risk, early-stage endometrial cancer patients," the lead author of the study, Marcus Randall, MD, of the University of Kentucky College of Medicine in Lexington, said in an ASTRO news release. (medpagetoday.com)
Including radiotherapy alone1
  • They were all treated with Intensity-modulated radiation therapy (IMRT) combined with systemic treatments, including radiotherapy alone (RT alone), neoadjuvant chemotherapy followed by radiotherapy (NACT+RT), CCRT, NACT+CCRT, NACT followed by radiotherapy and adjuvant chemotherapy (NACT+RT+AC), CCRT+AC and NACT+CCRT+AC. (oncotarget.com)
Either chemoradiotherapy2
Endometrial cancer4
  • However, the comparator was external-beam radiotherapy, and the study reaffirmed the role of chemotherapy for treating high risk endometrial cancer," she said. (medscape.com)
  • Among the treatments for improving survival in women with high-risk and early-stage endometrial cancer are radiation plus chemotherapy, vaginal cuff brachytherapy plus chemotherapy, and adjuvant chemotherapy. (medpagetoday.com)
  • The other study, PORTEC (Post-Operative Radiation Therapy in Endometrial Carcinoma), compared the standard of care with adjuvant chemotherapy during and after radiotherapy for patients with high-risk endometrial cancer. (medpagetoday.com)
  • Improving survival in women with high-risk, early-stage (stages I-II) endometrial cancer has been the goal of research exploring various modalities such as radiation plus chemotherapy, vaginal cuff brachytherapy plus chemotherapy, and adjuvant chemotherapy. (medpagetoday.com)
Resection2
  • Our patient has demonstrated a remarkable response to surgical decortication and resection with adjuvant rituximab - cyclophosphamide, doxorubicin, vincristine, prednisolone (R-CHOP) chemotherapy - and makes a case for routine debulking as part of the multimodality treatment of this unusual malignant complication of tuberculosis therapy. (rcpe.ac.uk)
  • The standard of care for patients with newly diagnosed GBM comprises maximum safe resection of the tumor followed by radiotherapy (RT) with concomitant and adjuvant temozolomide (TMZ) chemotherapy [ 3 , 4 ]. (springer.com)
Preoperative3
  • The present study aimed to compare the survival outcomes, acute toxicities and surgical complications in LARC patients who received preoperative chemoradiotherapy with triweekly oxaliplatin and capecitabine (triweekly XELOX) or capecitabine. (biomedcentral.com)
  • Methods: Between 2007 and 2017, patients with clinically staged II-III rectal cancer who were treated with preoperative chemoradiotherapy using either triweekly XELOX (oxaliplatin 130 mg/m 2 plus capecitabine 825 mg/m 2 ) or capecitabine were included. (biomedcentral.com)
  • However, the reports were both based on small sample sizes, and no clear evidence exists for the superiority of triweekly XELOX compared to capecitabine alone with preoperative chemoradiotherapy in patients with LARC. (biomedcentral.com)
Neoadjuvant chemoradiotherapy2
  • Two recent randomized trials have suggested benefit of neoadjuvant chemoradiotherapy over upfront surgery, both including single-agent chemotherapy regimens. (nih.gov)
  • Here, we review the literature and report a unique case of a patient with a vague presentation of esophageal neuroendocrine carcinoma as he enters his sixth year of survival following neoadjuvant chemoradiotherapy. (biomedcentral.com)
Toxicity1
  • There was also much more toxicity in patients given chemoradiotherapy, which occurred in 198 patients (60%), compared with only 41 patients (12%) who had radiation only. (medpagetoday.com)
Recurrence4
  • For this study, Matei and colleagues hypothesized that systemic chemotherapy and tumor volume-directed radiotherapy would improve recurrence-free survival and overall survival in comparison with systemic chemotherapy alone for patients with surgically staged III/IVA uterine cancer. (medscape.com)
  • The authors concluded that their data supported the clinical utility of ctDNA testing to identify residual disease and recurrence and that this was a potentially sensitive tool to determine which patients were at high risk of relapse and who could benefit from additional adjuvant therapy. (hospitalhealthcare.com)
  • Patients at high risk for tumor recurrence may benefit from more aggressive altered fractionation schedules in order to reduce the overall time from surgery to completion of radiotherapy. (biomedcentral.com)
  • However, in countries where D2 lymph node dissection is performed, the effect of radiotherapy on locoregional recurrence is controversial. (bezmialem.edu.tr)
Tumor1
  • Expression of the biomarker COX-2 on circulating tumor cells (CTCs) was found to have prognostic value in nasopharyngeal carcinoma (NPC) in relation to poor response to treatment, the risk of relapse and metastasis, and worse survival outcomes, researchers concluded in an article published in Radiotherapy and Oncology . (cancertherapyadvisor.com)
Pancreatic3
  • Investigating the translational potential of inhibiting AXL in combination with adjuvant chemotherapy in the treatment of pancreatic cancer. (cancerresearchuk.org)
  • The PREOPANC-2 trial investigates whether neoadjuvant FOLFIRINOX improves OS compared with neoadjuvant gemcitabine-based chemoradiotherapy and adjuvant gemcitabine in resectable and borderline resectable pancreatic cancer patients. (nih.gov)
  • The licensing agreement will bring together Ferronova's patented FerroTrace platform, a super-paramagnetic iron-oxide nanoparticle (SPION) formulation, and PRF's patented FAP inhibitor in a combination to be applied in targeted radiotherapy of difficult cancers with complicated treatment margins such as glioblastoma, prostate cancer, and pancreatic cancer. (axisimagingnews.com)
Combines chemotherapy2
Improves survival2
Systemic treatments1
  • The mainstay of treatment remains platinum-based doublet chemotherapy and despite benefits from prophylactic cranial radiation (PCI) and thoracic radiotherapy systemic treatments have not changed over the last few decades [ 5 - 7 ]. (biomedcentral.com)
Oncology1
  • This licensing and collaboration agreement is great news as it signals a new approach in targeted radiotherapy for the treatment of glioblastoma," says associate professor Hien Le, MD, a radiation oncologist at South Australia Health, Head of Research at the Department of Radiation Oncology at Royal Adelaide Hospital, and Associate Professor at the University of South Australia. (axisimagingnews.com)
Rectal2
  • Effective surgical adjuvant therapy for high-risk rectal carcinoma. (medscape.org)
  • 20 - 25 ] A major pooled analysis evaluating the impact of T and N stage and treatment on survival and relapse in patients with rectal cancer who are treated with adjuvant therapy confirmed these findings. (cancer.gov)
Patients treated1
  • METHODS: First, we retrospectively studied 60 advanced HNSCC patients treated with exclusive or adjuvant radiotherapy/chemoradiotherapy (RT/CRT). (unifi.it)
Radiation3
  • RADIOTHERAPY, ALSO KNOWN as radiation therapy, is a treatment where ionizing x-ray and gamma ray radiation are directed at tumors and used to kill cancer cells. (endalldisease.com)
  • Today, up to 60% of cancer patients receive radiotherapy as a part of their treatment regimens 1 and yet most are never fully aware of the risks involved with exposure to ionizing radiation. (endalldisease.com)
  • Currently adjuvant treatment is used after recovery from surgery such as radiation and chemotherapy. (afcr.org)
Treatment8
  • Patients receive 8 cycles of neoadjuvant FOLFIRINOX chemotherapy followed by surgery without adjuvant treatment (arm A), or 3 cycles of neoadjuvant gemcitabine with hypofractionated radiotherapy (36 Gy in 15 fractions) during the second cycle, followed by surgery and 4 cycles of adjuvant gemcitabine (arm B). The primary endpoint is OS by intention-to-treat. (nih.gov)
  • Clinical use of a combination of radiotherapy and chemotherapy continues to increase, while the development of immunotherapy, such as checkpoint inhibitors, offers hope in improving treatment outcome. (hkmj.org)
  • According to the systemic treatment modalities delivered, we classified all 547 patients into non-adjuvant chemotherapy (non-AC) group (341 patients) and adjuvant chemotherapy (AC) group (206 patients). (oncotarget.com)
  • Guidelines recommend adjuvant treatment when positive lymph nodes are found after surgical treatment for squamous cell cancer of the vulva except for cases with a single occult intranodal metastasis. (dermatoljournal.com)
  • aTTom - adjuvant Tamoxifen Treatment Offer more? (birmingham.ac.uk)
  • Due to its rarity, no standardized guidelines have been proposed to treat esophageal neuroendocrine carcinoma, although general recommendations suggest surgery with adjuvant chemoradiotherapy as the treatment of choice. (biomedcentral.com)
  • Comparison of two different adjuvant treatment modalities for pN3 gastric cancer patients after D2 lymph node dissection: can we avoid radiotherapy in a subgroup of patients? (bezmialem.edu.tr)
  • The aim of this study is to compare the outcomes in pN3 gastric cancer patients following two adjuvant treatment modalities: chemotherapy (CT) and CRT after D2 lymph node dissection. (bezmialem.edu.tr)
Fluorouracil2
Surgery1
  • Glioblastoma is the most common and aggressive primary malignant tumour of the central nervous system, and the current standard of care comprises cytoreductive surgery followed by adjuvant chemoradiotherapy. (axisimagingnews.com)
Randomly assigned to receive1
  • In the six trials of interest, a total of 988 patients with locally advanced HNSCC were randomly assigned to receive either accelerated or conventionally fractionated adjuvant radiotherapy. (biomedcentral.com)
Squamous1
Therapy3
  • Of the 10-20% of patients who present with resectable tumors, the 5-year surviva rate is still only about 20%, with a median survival of around 23-43 months with adjuvant therapy ( 2 - 4 ). (iiarjournals.org)
  • More than half of Korean lung cancer patients undergo chemotherapy, including adjuvant therapy. (bvsalud.org)
  • The National Comprehensive Cancer Network (NCCN) guidelines have been updated recently for targeted therapy of multiple gene mutations, and targeted therapy is used not only for chemotherapy but also for adjuvant therapy. (bvsalud.org)
Relapse1
  • At 60 months, the percentage of patients alive and relapse free was 59% in the chemoradiotherapy group and 58% in the chemotherapy-only group (hazard ratio [HR], 0.90). (medscape.com)
Trials1
  • There are limited data of randomized clinical trials with adjuvant chemotherapy to support evidence-based decision-making [ 6 - 8 ]. (oncotarget.com)
Oxaliplatin1
  • Oxaliplatin/5FU/LV in adjuvant colon cancer: updated efficacy results of the MOSAIC trial, including survival, with a median follow-up of six years [abstract]. (medscape.org)
Survival in patients1
  • To evaluate the effect of timing of radiotherapy (RT) on survival in patients with newly diagnosed primary glioblastoma (GBM) treated with the same therapeutical protocol. (springer.com)
Positive nodes1
  • Recent studies questioned these recommendations and showed benefit of adjuvant radiotherapy for all patients with positive nodes irrespective of number of nodes. (dermatoljournal.com)
Cancers1
Lung cancer1
  • Palliative Radiotherapy for Non-metastatic Non-small-cell Lung Cancer: Impact of Blood Test Results on Survival. (cdc.gov)
Median1
  • With a median follow-up time of 53.8 months, adjuvant chemotherapy significantly decreased the risk of distant metastasis (HR 0.413, 95% CI 0.194-0.881, p = 0.022) as well as significantly increased the OS (HR 0.398, 95% CI 0.187-0.848, p = 0.017) in patients with N3 disease. (oncotarget.com)
Determine the optimal1
  • In February 1998 she joined the CRCTU as a Trial Coordinator coordinating a national, multicentre, phase III, trial called SECRAB which was designed to determine the optimal sequence of chemotherapy and radiotherapy in patients with early breast cancer. (birmingham.ac.uk)
High-risk1
  • Accelerated radiotherapy does not result in a significant improvement of loco-regional control or overall survival in high-risk patients. (biomedcentral.com)
Metastasis1
  • When these variables are taken into account, adjuvant radiotherapy does not seem to result in a better survival for patients with a single occult intranodal metastasis. (dermatoljournal.com)
Combination1
Standard of c1
Significantly1
  • Accelerated radiotherapy did not improve the loco-regional control ( n = 988, HR = 0.740, CI = 0.48-1.13, p = 0.162), progression-free survival (HR = 0.89, CI = 0.76-1.04, p = 0.132) or overall survival (HR = 0.88, CI = 0.75-1.04, p = 0.148) significantly. (biomedcentral.com)
Results1
  • Whether the addition of chemotherapy to the radiotherapy for patients with more than one positive node or extracapsular spread results in a better survival remains uncertain. (dermatoljournal.com)